Phase 1 Trial of THC Softgels: Safe up to 20 mg Daily but Better Tolerated After First Day
A Phase 1 trial of THC-dominant softgels (5-20 mg THC daily) in 41 healthy adults found all adverse events were mild to moderate, with most occurring on the first day. Subjective effects were noticeable only at the highest dose.
Quick Facts
What This Study Found
All 65 adverse events were mild-to-moderate; none were serious. Most adverse events (30/65) occurred on the first treatment day, suggesting tolerance develops quickly. At the highest dose (20 mg THC daily), participants reported feeling "any effect" and "dazed" compared to placebo. The recommended starting dose was 10 mg THC daily.
Key Numbers
41 participants. Doses: 5-20 mg THC daily. All 65 AEs mild-moderate. Most common: somnolence (8), lethargy (7), headache (5). 30/65 AEs on first day. Subjective effects ("feel any effect," "dazed") significantly different from placebo only at 20 mg. Recommended start: ≤10 mg THC daily.
How They Did This
Phase 1, multiple-dose, randomized, placebo-controlled study. 41 healthy participants received one of four THC doses (5-20 mg/day with minimal CBD) or placebo, administered every 12 hours with food for 7 days. Safety, plasma drug levels, and self-reported subjective effects were measured.
Why This Research Matters
Like its companion CBD study, this provides pharmaceutical-grade dosing data for THC. The finding that most side effects occur on Day 1 and then improve supports the clinical practice of starting low and titrating slowly.
The Bigger Picture
Together with the companion Spectrum Yellow (CBD-dominant) study, this provides a comprehensive dosing framework for standardized cannabis products. The clear first-day effect followed by tolerance is consistent with clinical experience and supports the "start low, go slow" approach.
What This Study Doesn't Tell Us
Healthy participants only, short 7-day duration. The THC doses tested (5-20 mg) represent the lower end of what some medical cannabis patients use. CBD content was minimal (<0.25 mg/day), so this reflects a THC-dominant profile only.
Questions This Raises
- ?How would these results differ in patients with chronic pain or other conditions where THC tolerance may already exist?
- ?Does the rapid tolerance to first-day effects extend to therapeutic effects as well?
Trust & Context
- Key Stat:
- 30 of 65 adverse events occurred on the first treatment day
- Evidence Grade:
- Moderate: randomized, placebo-controlled Phase 1 design, but small sample and healthy participants only.
- Study Age:
- Published in 2022.
- Original Title:
- Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
- Published In:
- Journal of analytical toxicology, 46(5), 528-539 (2022)
- Authors:
- Peters, Erica N(8), Mosesova, Irina(2), MacNair, Laura(3), Vandrey, Ryan, Land, M Hunter, Ware, Mark A, Turcotte, Cynthia, Bonn-Miller, Marcel O
- Database ID:
- RTHC-04142
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Will THC side effects get better over time?
In this study, most side effects (somnolence, lethargy, headache) occurred on the first day of treatment and decreased after that, suggesting rapid tolerance to acute effects. The recommended approach is to start at 10 mg daily or less and increase gradually.
At what dose does THC cause noticeable effects?
In this study of cannabis-naive healthy adults, subjective effects like feeling "dazed" were only significantly different from placebo at the highest dose of 20 mg THC daily. Lower doses (5-15 mg) did not produce consistent subjective effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-epilepsy-CBD-Epidiolex
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- medical-benefits-of-cannabis
- quitting-weed-and-alcohol
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- rehab-for-weed-addiction-necessary
- seniors-older-adults-cannabis-risks-medications
- signs-of-cannabis-use-disorder
- weed-breastfeeding-THC-breast-milk
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-04142APA
Peters, Erica N; Mosesova, Irina; MacNair, Laura; Vandrey, Ryan; Land, M Hunter; Ware, Mark A; Turcotte, Cynthia; Bonn-Miller, Marcel O. (2022). Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.. Journal of analytical toxicology, 46(5), 528-539. https://doi.org/10.1093/jat/bkab035
MLA
Peters, Erica N, et al. "Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.." Journal of analytical toxicology, 2022. https://doi.org/10.1093/jat/bkab035
RethinkTHC
RethinkTHC Research Database. "Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Re..." RTHC-04142. Retrieved from https://rethinkthc.com/research/peters-2022-safety-pharmacokinetics-and-pharmacodynamics-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.